This document lists the clinical and administrative information required to support prior authorization (PA) requests for specialty and other Part D outpatient prescription drugs on Independent Health Medicare Advantage formularies. It explains that prior authorization is required for drugs designated with 'PA' on the formularies and that lack of PA may result in noncoverage, so providers must obtain approval before a prescription is filled (see contact information and formulary applicability).
The policy defines the typical components of PA submissions: a confirmed diagnosis, required objective testing (for example, genetic or tumor testing, hemodynamic data, biopsy or histology, 24‑hour urine or blood biomarkers), baseline safety labs and physiologic measures (e.g., LFTs, electrolytes, creatinine clearance, QTc/QTcF), documentation of prior or concomitant therapies and reasons for failure or intolerance, prescriber specialty consistency, and patient age/ pregnancy status when applicable. Many drug entries also include specific exclusions (for example, pregnancy, moderate/severe hepatic impairment, or contraindicated drug interactions) and explicit coverage durations (commonly 1 year, with some initial shorter durations such as 6 months for selected products).
Providers should follow the product‑specific criteria in this document when preparing PA requests — including the exact diagnostic confirmations, threshold values, prior‑therapy trials, and specialist prescriber requirements — because approvals are granted only when the documented evidence meets the stated criteria.